CN104379134A - 肠外艾司洛尔剂型 - Google Patents

肠外艾司洛尔剂型 Download PDF

Info

Publication number
CN104379134A
CN104379134A CN201380028099.XA CN201380028099A CN104379134A CN 104379134 A CN104379134 A CN 104379134A CN 201380028099 A CN201380028099 A CN 201380028099A CN 104379134 A CN104379134 A CN 104379134A
Authority
CN
China
Prior art keywords
solution
dosage form
esmolol hydrochloride
esmolol
parenteral solutions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380028099.XA
Other languages
English (en)
Chinese (zh)
Inventor
R·威德曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AOP Orphan Pharmaceuticals AG
Original Assignee
AOP Orphan Pharmaceuticals AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48407551&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN104379134(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by AOP Orphan Pharmaceuticals AG filed Critical AOP Orphan Pharmaceuticals AG
Publication of CN104379134A publication Critical patent/CN104379134A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201380028099.XA 2012-05-10 2013-05-08 肠外艾司洛尔剂型 Pending CN104379134A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12167443.6 2012-05-10
EP12167443 2012-05-10
PCT/EP2013/059594 WO2013167657A1 (en) 2012-05-10 2013-05-08 Parenteral esmolol formulation

Publications (1)

Publication Number Publication Date
CN104379134A true CN104379134A (zh) 2015-02-25

Family

ID=48407551

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380028099.XA Pending CN104379134A (zh) 2012-05-10 2013-05-08 肠外艾司洛尔剂型

Country Status (27)

Country Link
US (3) US20150087704A1 (enExample)
EP (1) EP2846776B1 (enExample)
JP (1) JP6220383B2 (enExample)
CN (1) CN104379134A (enExample)
AU (1) AU2013258031B2 (enExample)
BR (1) BR112014027870B1 (enExample)
CA (1) CA2872953C (enExample)
CL (1) CL2014003028A1 (enExample)
DK (1) DK2846776T3 (enExample)
EA (1) EA032344B1 (enExample)
ES (1) ES2794093T3 (enExample)
HR (1) HRP20200897T1 (enExample)
HU (1) HUE049314T2 (enExample)
IL (1) IL235497A0 (enExample)
LT (1) LT2846776T (enExample)
MA (1) MA37500B1 (enExample)
MX (1) MX374771B (enExample)
MY (1) MY173900A (enExample)
NZ (1) NZ701429A (enExample)
PH (1) PH12014502494B1 (enExample)
PL (1) PL2846776T3 (enExample)
PT (1) PT2846776T (enExample)
SI (1) SI2846776T1 (enExample)
TN (1) TN2014000464A1 (enExample)
UA (1) UA115333C2 (enExample)
WO (1) WO2013167657A1 (enExample)
ZA (1) ZA201408149B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019122157A1 (en) * 2017-12-21 2019-06-27 Ipsol Ag A lyophilisate comprising esmolol and adenosine for use in cardioplegia
CN111848420A (zh) * 2020-07-22 2020-10-30 杭州煌森生物科技有限公司 一种盐酸艾司洛尔的新晶型及制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101674803A (zh) * 2007-05-22 2010-03-17 巴克斯特国际公司 浓艾司洛尔

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6310094B1 (en) * 2001-01-12 2001-10-30 Baxter International Inc. Ready-to-use esmolol solution
TWI277414B (en) 2001-01-12 2007-04-01 Baxter Int Esmolol formulation
SE0401842D0 (sv) * 2004-07-12 2004-07-12 Dizlin Medical Design Ab Infusion and injection solution of levodopa
WO2007026771A1 (ja) * 2005-08-31 2007-03-08 Ono Pharmaceutical Co., Ltd. 点滴用注射剤
JP5623288B2 (ja) 2007-12-21 2014-11-12 エイオーピーオーファン ファーマスーティカルズ アクチエンゲゼルシャフトＡＯＰ Ｏｒｐｈａｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 医薬組成物
CN102106846A (zh) * 2009-12-23 2011-06-29 南京海辰药业有限公司 左旋盐酸艾司洛尔药物组合物及其制备方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101674803A (zh) * 2007-05-22 2010-03-17 巴克斯特国际公司 浓艾司洛尔

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: ""ESMOCARD LYO 2500 mg powder for concentrate for solution for infusion"", 《URL:HTTP://DB.CBG-MEB.NL/MRI/SPC/NLH-0779-003.PDF》, 7 September 2010 (2010-09-07) *
ANONYMOUS: ""PACKAGE LEAFLET:INFORMATION FOR THE USER:ESMOCARD LYO"", 《URL:HTTP://DB.CBG-MEB.NL/MRI/PIL/NLH-0779-003.PDF》, 9 November 2010 (2010-11-09) *
ANONYMOUS: ""Product Name in the PMS:Esmocard Lyo"", 《URL:HTTP://MRI.MEDAGENCIES.ORG/HUMAN/PRODUCT/DETAILS/2363》, 20 December 2011 (2011-12-20) *
HANTZEN STEVENSON: ""PUBLIC ASSESSMENT REPORT of the Medicines Evaluation Board in the Netherlands:Esmolol HCl LYO Orpha 2500 mg powder for concentrate solution for infusion"", 《URL:HTTP://DB.CBG-MEB.NL/MRI/PAR/NLH-0779-003.PDF》, 4 January 2011 (2011-01-04) *

Also Published As

Publication number Publication date
US20150087704A1 (en) 2015-03-26
CA2872953A1 (en) 2013-11-14
TN2014000464A1 (en) 2016-03-30
MX2014013556A (es) 2015-01-16
AU2013258031B2 (en) 2017-08-03
MY173900A (en) 2020-02-26
EP2846776B1 (en) 2020-04-15
SI2846776T1 (sl) 2020-08-31
EA201491841A1 (ru) 2015-02-27
PH12014502494B1 (en) 2019-11-13
WO2013167657A1 (en) 2013-11-14
BR112014027870A8 (pt) 2023-01-17
IL235497A0 (en) 2014-12-31
MA37500B1 (fr) 2016-12-30
ZA201408149B (en) 2016-08-31
HUE049314T2 (hu) 2020-09-28
PL2846776T3 (pl) 2020-09-21
MA37500A1 (fr) 2016-03-31
DK2846776T3 (da) 2020-06-15
AU2013258031A1 (en) 2014-11-20
EA032344B1 (ru) 2019-05-31
BR112014027870A2 (pt) 2017-06-27
US11963940B2 (en) 2024-04-23
JP6220383B2 (ja) 2017-10-25
ES2794093T3 (es) 2020-11-17
CA2872953C (en) 2020-04-07
PH12014502494A1 (en) 2015-01-12
US20170326095A1 (en) 2017-11-16
US20220249424A1 (en) 2022-08-11
CL2014003028A1 (es) 2015-06-19
EP2846776A1 (en) 2015-03-18
UA115333C2 (uk) 2017-10-25
HRP20200897T1 (hr) 2020-11-27
BR112014027870B1 (pt) 2023-04-25
HK1204265A1 (en) 2015-11-13
JP2015520142A (ja) 2015-07-16
PT2846776T (pt) 2020-05-28
MX374771B (es) 2025-03-06
NZ701429A (en) 2016-04-29
LT2846776T (lt) 2020-06-25

Similar Documents

Publication Publication Date Title
EP2635269B1 (en) A combination composition
CN104302291A (zh) 苯达莫司汀的制剂
JP2018531268A (ja) ダントロレンを含む水性組成物
JP2018531268A6 (ja) ダントロレンを含む水性組成物
US11963940B2 (en) Parenteral esmolol formulation
CA3210407A1 (en) Low-sorbing glyburide formulation and methods
RU2493824C2 (ru) Концентрат эсмолола
CN107106659B (zh) 肠胃外胰高血糖素制剂
BR112020014719A2 (pt) Tratamento de hipoglicemia pós-bariátrica usando glucagon estável em minidose
JP6629850B2 (ja) 汎用心停止液（変種）
JP2004149495A (ja) 電解質代謝および酸塩基平衡を管理する方法
CN103340863A (zh) 烟酰胺在制备治疗糖尿病伤口愈合药物中的应用
CN102885766B (zh) 一种右旋酮洛芬注射液及其制备方法
JP2022089867A (ja) 安定なイブプロフェン注射製剤用組成物
HK1204265B (en) Parenteral esmolol formulation
Gonenavar et al. High concentration Amiodarone continuous infusion induced Phlebitis: A Case Report.
AU2014203121B2 (en) Concentrate esmolol
Walsh et al. A pediatric case study of treprostinil overdose
TWI619716B (zh) 含維生素ｃ或其衍生物的替莫唑胺醫藥組成物及其製備方法
JP2002538119A (ja) 血圧低下のためのレミフェンタニルの使用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20150225